News Focus
News Focus
Followers 34
Posts 11444
Boards Moderated 0
Alias Born 01/12/2016

Re: Doc logic post# 774168

Friday, 07/04/2025 11:09:10 AM

Friday, July 04, 2025 11:09:10 AM

Post# of 822496
Here is quick summary from AI
So I don’t know what do you want FDA , you want FDA to do something they don’t do , and that too for a small , practically unknown company on an OTC , before company agrees to submit a formal application :
,
“🔹 The FDA does not “approve” a Statistical Analysis Plan (SAP) in the sense of issuing a formal approval letter like it does for a drug or device marketing application. Instead:

✅ FDA reviews and accepts the SAP as part of the overall trial protocol during the Investigational New Drug (IND) or Biologics License Application (BLA) process.
✅ The SAP becomes a binding part of the trial protocol that sponsors must follow once agreed with the FDA.
✅ If the SAP is modified after initial agreement, significant changes may require protocol amendments, which the FDA must again review and accept.

?

🚫 But the FDA does not grant an “SAP approval” certificate or decision. There’s no official “stamp of approval” issued specifically for the SAP alone.

?

🔎 What happens in practice:
• Sponsors typically submit their SAP as part of their trial protocol or as a separate document during the IND phase.
• The FDA may provide comments, request clarifications, or recommend changes.
• Once the sponsor addresses these, the FDA’s acceptance effectively indicates that the plan is adequate for evaluating trial data, but not formally “approved.”

?

📌 Key takeaway:

The FDA’s role is to accept an SAP as adequate for the trial’s intended endpoints, but it does not approve SAPs as standalone regulatory actions.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News